// App-Quantinova.ai

4074 : A phaseII study of antiPD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.

Researchers

Presenter

  • Shukui Qin

Principal Investigators

  • Zhendong Chen

  • Ying Liu

  • Jianping Xiong

  • Zhenggang Ren

  • Zhiqiang Meng

  • ShanZhi Gu

  • Linna Wang

  • Jianjun Zou

Medical Centers

  • Jinling Hospital, Nanjing, China

  • Department of Pediatrics, The Second Hospital of Anhui Medical University, Hefei, China

  • Department of Medical Oncology, Zhejiang Cancer Hospital, Zhejiang, China

  • Department of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, China

  • Department of Pathology, Zhong Shan Hospital, Fudan University, Shanghai, China

  • Department of Traditional Chinese Medicine, Fudan University Shanghai Cancer Center, Shanghai, China

  • Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China

  • Jiangsu Hengrui Medicine Co., Ltd., Shanghai, China

Locations

  • China

Companies

  • Jiangsu Hengrui Phar

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • Camrelizumab

  • Gemcitabine

  • Oxaliplatin

  • leucovorin

  • FOLFOX 4

Outcome

  • N/A


Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03092895

Sponsors

  • N/A

Result

  • Final